Literature DB >> 1148507

Alternative approaches to analgesia: baclofen as a model compound.

D A Cutting, C C Jordan.   

Abstract

1 It is suggested that analgesia could be produced by drug action at the spinal level through (a) interference with neurotransmission at primary afferent terminals; (b) enhancement of the ;gate control' of the sensory input to the spinal cord mediated through descending spinal tracts; or (c) increased presynaptic inhibition of primary afferents by a direct action.2 Baclofen (9.4-70.3 mumol/kg, i.p.), which may mimic spinal presynaptic inhibition, produced a dose-dependent increase in the response times of mice in a hot-plate test, but high doses also impaired motor function.3 Morphine hydrochloride (5.3-40 mumol/kg, i.p.) increased the response time of mice in the hot-plate test and had little effect on motor function.4 Combination of baclofen (9.4 or 23.4 mumol/kg) with morphine (13.3 mumol/kg) produced greater increases in response time than either drug administered alone but with little concurrent effect on motor function.5 The possibility that baclofen may have some analgesic action and a potentiating effect on other analgesics is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1148507      PMCID: PMC1666634          DOI: 10.1111/j.1476-5381.1975.tb06926.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  PHARMACOLOGICAL STUDIES ON PRESYNAPTIC INHIBITION.

Authors:  J C ECCLES; R SCHMIDT; W D WILLIS
Journal:  J Physiol       Date:  1963-10       Impact factor: 5.182

2.  Presynaptic inhibition of the spinal monosynaptic reflex pathway.

Authors:  J C ECCLES; R F SCHMIDT; W D WILLIS
Journal:  J Physiol       Date:  1962-05       Impact factor: 5.182

3.  The cytoarchitectonic organization of the spinal cord in the cat.

Authors:  B REXED
Journal:  J Comp Neurol       Date:  1952-06       Impact factor: 3.215

4.  Central effects of beta-(para-chlorophenyl)-gamma-aminobutyric acid.

Authors:  D R Curtis; C J Game; G A Johnston; R M McCulloch
Journal:  Brain Res       Date:  1974-04-26       Impact factor: 3.252

5.  Bicuculline, an antagonist of GABA and synaptic inhibition in the spinal cord of the cat.

Authors:  D R Curtis; A W Duggan; D Felix; G A Johnston
Journal:  Brain Res       Date:  1971-09-10       Impact factor: 3.252

6.  The antagonism of the glutamate-induced and synaptic excitations of thalamic neurones.

Authors:  S Haldeman; R D Huffman; K C Marshall; H McLennan
Journal:  Brain Res       Date:  1972-04-28       Impact factor: 3.252

Review 7.  Pain mechanisms: a new theory.

Authors:  R Melzack; P D Wall
Journal:  Science       Date:  1965-11-19       Impact factor: 47.728

8.  The effects of substance P and other peptides on spinal neurons of the frog.

Authors:  S Konishi; M Otsuka
Journal:  Brain Res       Date:  1974-01-18       Impact factor: 3.252

9.  The role of gamma-aminobutyric acid as a mediator of positive dorsal root potentials.

Authors:  R A Levy; E G Anderson
Journal:  Brain Res       Date:  1974-08-09       Impact factor: 3.252

10.  Studies on heptazone (6-morpholino-4,4-diphenyl-3-heptanone hydrochloride) in comparison with other analgesic drugs.

Authors:  C A WINTER; L FLATAKER
Journal:  J Pharmacol Exp Ther       Date:  1950-03       Impact factor: 4.030

View more
  13 in total

1.  The differential effects of baclofen on segmental and descending excitation of spinal interneurones in the cat.

Authors:  D R Curtis; R Malik
Journal:  Exp Brain Res       Date:  1985       Impact factor: 1.972

2.  Type B GABA receptors contribute to the restoration of balance during vestibular compensation in mice.

Authors:  R Heskin-Sweezie; H K Titley; J S Baizer; D M Broussard
Journal:  Neuroscience       Date:  2010-04-13       Impact factor: 3.590

3.  GABA, glutamate and substance P-like immunoreactivity release: effects of novel GABAB antagonists.

Authors:  H Teoh; M Malcangio; N G Bowery
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

4.  CGP 35348, a new GABAB antagonist, prevents antinociception and muscle-relaxant effect induced by baclofen.

Authors:  M Malcangio; C Ghelardini; A Giotti; P Malmberg-Aiello; A Bartolini
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

5.  Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice.

Authors:  Xia Li; Victoria B Risbrough; Chelsea Cates-Gatto; Katarzyna Kaczanowska; M G Finn; Amanda J Roberts; Athina Markou
Journal:  Neuropharmacology       Date:  2013-01-29       Impact factor: 5.250

6.  Central effects of baclofen on the L-dopa induced hyperactive urinary bladder of the rat.

Authors:  U Sillén; B Persson; A Rubenson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-09       Impact factor: 3.000

7.  Hyperpolarization by GABAB receptor agonists in mid-brain periaqueductal gray neurones in vitro.

Authors:  B Chieng; M J Christie
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

8.  Relative activities of substance P-related peptides in the guinea-pig ileum and rat parotid gland, in vitro.

Authors:  P R Gater; C C Jordan; D G Owen
Journal:  Br J Pharmacol       Date:  1982-02       Impact factor: 8.739

9.  Lack of effect of baclofen on substance P and somatostatin release from the spinal cord in vitro.

Authors:  J Sawynok; N Kato; V Havlicek; F S LaBella
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-04       Impact factor: 3.000

10.  Some pharmacological studies on the spastic mouse.

Authors:  T J Biscoe; J P Fry
Journal:  Br J Pharmacol       Date:  1982-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.